Gerard Pasterkamp, MD, is Professor of Experimental Cardiology and his research is embedded in the laboratory of clinical chemistry, UMC Utrecht, the Netherlands. The laboratory houses researchers and technicians that cover a broad range of activities. His research interests are in the field of cardiovascular biology and more specifically innovation in biomarkers and drug targets. The research group houses the largest atherosclerotic plaque biobank worldwide: Arhero-Express including >4000 patients This biobank has generated new insights into determinants of plaque destabilisation. For example, it has been demonstrated that local plaque characteristics are strongly associated with long term outcome but also that plaque characteristics have rapidly changed in the last decade. The laboratory now invests in the excavation of genetic determinants of atherosclerotic plaque characteristics. Recent insights in the mechanisms of atherosclerosis progression have been obtained by executing whole genome SNP analyses and plaque DNA methylation as well as single cell sequencing.
Private public research projects are one of the main core-activities within the laboratory of experimental cardiology. Within the laboratories spin off activities are stimulated. He coordinates national and EU based consortia with the aim to unravel biomarkers and mechanisms of atherosclerotic disease. His translational profile is noted in the private public consortia he is involved in. He is supervising three public private grants that have been rewarded with the aim to develop novel biomarkers and imaging technology to detect cardiac ischemia and endothelial dysfunction. In 2018 he obtained a LeDucq grant together with Prof G Owens (Virginia University) on the role of smooth muscle cell plasticity in the atherosclerotic plaque.